Lithuanian Prostate Diagnostics Implementation Guide
0.0.1 - ci-build
Lithuanian Prostate Diagnostics Implementation Guide
0.0.1 - ci-build
Lithuanian Prostate Diagnostics Implementation Guide, published by Lithuanian Medical Library. This guide is not an authorized publication; it is the continuous build for version 0.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7LT/ig-lt-prostate/ and changes regularly. See the Directory of published versions
| Draft nuo 2026-03-31 |
{
"resourceType" : "CodeSystem",
"id" : "prostate-questionnaire-options",
"language" : "lt",
"text" : {
"status" : "generated",
"div" : "<div xml:lang=\"lt\" lang=\"lt\"><hr/><p><b>Lithuanian</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem prostate-questionnaire-options</b></p><a name=\"lt-prostate-questionnaire-options\"> </a><a name=\"lt-hcprostate-questionnaire-options\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p></div><p>This case-sensitive code system <code>https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">specimen-satisfactory<a name=\"lt-prostate-questionnaire-options-specimen-satisfactory\"> </a></td><td>Specimen satisfactory for evaluation</td></tr><tr><td style=\"white-space:nowrap\">specimen-limited<a name=\"lt-prostate-questionnaire-options-specimen-limited\"> </a></td><td>Specimen satisfactory but limited</td></tr><tr><td style=\"white-space:nowrap\">specimen-insufficient<a name=\"lt-prostate-questionnaire-options-specimen-insufficient\"> </a></td><td>Insufficient tissue for diagnosis</td></tr><tr><td style=\"white-space:nowrap\">treatment-unknown<a name=\"lt-prostate-questionnaire-options-treatment-unknown\"> </a></td><td>Treatment effect unknown</td></tr><tr><td style=\"white-space:nowrap\">treatment-unidentifiable<a name=\"lt-prostate-questionnaire-options-treatment-unidentifiable\"> </a></td><td>Treatment effect unidentifiable</td></tr><tr><td style=\"white-space:nowrap\">treatment-radiotherapy<a name=\"lt-prostate-questionnaire-options-treatment-radiotherapy\"> </a></td><td>Observed radiotherapy effect</td></tr><tr><td style=\"white-space:nowrap\">treatment-hormone<a name=\"lt-prostate-questionnaire-options-treatment-hormone\"> </a></td><td>Observed hormone therapy effect</td></tr><tr><td style=\"white-space:nowrap\">treatment-other<a name=\"lt-prostate-questionnaire-options-treatment-other\"> </a></td><td>Observed other therapy effect</td></tr><tr><td style=\"white-space:nowrap\">hist-acinar<a name=\"lt-prostate-questionnaire-options-hist-acinar\"> </a></td><td>Acinar adenocarcinoma (conventional)</td></tr><tr><td style=\"white-space:nowrap\">hist-acinar-signet-ring<a name=\"lt-prostate-questionnaire-options-hist-acinar-signet-ring\"> </a></td><td>Acinar adenocarcinoma, signet-ring cell-like</td></tr><tr><td style=\"white-space:nowrap\">hist-acinar-pleomorphic<a name=\"lt-prostate-questionnaire-options-hist-acinar-pleomorphic\"> </a></td><td>Acinar adenocarcinoma, pleomorphic giant cell</td></tr><tr><td style=\"white-space:nowrap\">hist-acinar-sarcomatoid<a name=\"lt-prostate-questionnaire-options-hist-acinar-sarcomatoid\"> </a></td><td>Acinar adenocarcinoma, sarcomatoid</td></tr><tr><td style=\"white-space:nowrap\">hist-acinar-pin-like<a name=\"lt-prostate-questionnaire-options-hist-acinar-pin-like\"> </a></td><td>Acinar adenocarcinoma, PIN-like</td></tr><tr><td style=\"white-space:nowrap\">hist-idc-isolated<a name=\"lt-prostate-questionnaire-options-hist-idc-isolated\"> </a></td><td>Isolated intraductal carcinoma</td></tr><tr><td style=\"white-space:nowrap\">hist-ductal<a name=\"lt-prostate-questionnaire-options-hist-ductal\"> </a></td><td>Ductal adenocarcinoma</td></tr><tr><td style=\"white-space:nowrap\">hist-adenosquamous<a name=\"lt-prostate-questionnaire-options-hist-adenosquamous\"> </a></td><td>Adenosquamous carcinoma</td></tr><tr><td style=\"white-space:nowrap\">hist-squamous<a name=\"lt-prostate-questionnaire-options-hist-squamous\"> </a></td><td>Squamous cell carcinoma</td></tr><tr><td style=\"white-space:nowrap\">hist-basal-cell<a name=\"lt-prostate-questionnaire-options-hist-basal-cell\"> </a></td><td>Basal cell (adenoid cystic) carcinoma</td></tr><tr><td style=\"white-space:nowrap\">hist-neuro-adeno<a name=\"lt-prostate-questionnaire-options-hist-neuro-adeno\"> </a></td><td>Adenocarcinoma with neuroendocrine differentiation</td></tr><tr><td style=\"white-space:nowrap\">hist-neuro-well-diff<a name=\"lt-prostate-questionnaire-options-hist-neuro-well-diff\"> </a></td><td>Well-differentiated neuroendocrine tumor</td></tr><tr><td style=\"white-space:nowrap\">hist-neuro-small-cell<a name=\"lt-prostate-questionnaire-options-hist-neuro-small-cell\"> </a></td><td>Small cell neuroendocrine carcinoma</td></tr><tr><td style=\"white-space:nowrap\">hist-neuro-large-cell<a name=\"lt-prostate-questionnaire-options-hist-neuro-large-cell\"> </a></td><td>Large cell neuroendocrine carcinoma</td></tr><tr><td style=\"white-space:nowrap\">hist-unassessable<a name=\"lt-prostate-questionnaire-options-hist-unassessable\"> </a></td><td>Carcinoma, type unassessable</td></tr><tr><td style=\"white-space:nowrap\">hist-other<a name=\"lt-prostate-questionnaire-options-hist-other\"> </a></td><td>Other histological type (see comment)</td></tr><tr><td style=\"white-space:nowrap\">isup-gg1<a name=\"lt-prostate-questionnaire-options-isup-gg1\"> </a></td><td>ISUP Grade Group 1 (Gleason 3+3)</td></tr><tr><td style=\"white-space:nowrap\">isup-gg2<a name=\"lt-prostate-questionnaire-options-isup-gg2\"> </a></td><td>ISUP Grade Group 2 (Gleason 3+4)</td></tr><tr><td style=\"white-space:nowrap\">isup-gg3<a name=\"lt-prostate-questionnaire-options-isup-gg3\"> </a></td><td>ISUP Grade Group 3 (Gleason 4+3)</td></tr><tr><td style=\"white-space:nowrap\">isup-gg4<a name=\"lt-prostate-questionnaire-options-isup-gg4\"> </a></td><td>ISUP Grade Group 4 (Gleason 4+4 or equivalent)</td></tr><tr><td style=\"white-space:nowrap\">isup-gg5<a name=\"lt-prostate-questionnaire-options-isup-gg5\"> </a></td><td>ISUP Grade Group 5 (Gleason 4+5 / 5+4 / 5+5)</td></tr><tr><td style=\"white-space:nowrap\">idc-absent<a name=\"lt-prostate-questionnaire-options-idc-absent\"> </a></td><td>Intraductal carcinoma not identified</td></tr><tr><td style=\"white-space:nowrap\">idc-present<a name=\"lt-prostate-questionnaire-options-idc-present\"> </a></td><td>Intraductal carcinoma identifiable</td></tr><tr><td style=\"white-space:nowrap\">cribriform-na<a name=\"lt-prostate-questionnaire-options-cribriform-na\"> </a></td><td>Cribriform not applicable</td></tr><tr><td style=\"white-space:nowrap\">cribriform-unknown<a name=\"lt-prostate-questionnaire-options-cribriform-unknown\"> </a></td><td>Cribriform undefined</td></tr><tr><td style=\"white-space:nowrap\">cribriform-present<a name=\"lt-prostate-questionnaire-options-cribriform-present\"> </a></td><td>Cribriform identifiable</td></tr><tr><td style=\"white-space:nowrap\">dre-not-done<a name=\"lt-prostate-questionnaire-options-dre-not-done\"> </a></td><td>DRE not performed</td></tr><tr><td style=\"white-space:nowrap\">dre-normal<a name=\"lt-prostate-questionnaire-options-dre-normal\"> </a></td><td>DRE normal</td></tr><tr><td style=\"white-space:nowrap\">dre-suspicious<a name=\"lt-prostate-questionnaire-options-dre-suspicious\"> </a></td><td>DRE suspicious</td></tr><tr><td style=\"white-space:nowrap\">referral-screening<a name=\"lt-prostate-questionnaire-options-referral-screening\"> </a></td><td>Referral for screening</td></tr><tr><td style=\"white-space:nowrap\">referral-elevated-psa<a name=\"lt-prostate-questionnaire-options-referral-elevated-psa\"> </a></td><td>Referral for elevated PSA</td></tr><tr><td style=\"white-space:nowrap\">referral-other<a name=\"lt-prostate-questionnaire-options-referral-other\"> </a></td><td>Other referral reason</td></tr><tr><td style=\"white-space:nowrap\">ynk-yes<a name=\"lt-prostate-questionnaire-options-ynk-yes\"> </a></td><td>Yes</td></tr><tr><td style=\"white-space:nowrap\">ynk-no<a name=\"lt-prostate-questionnaire-options-ynk-no\"> </a></td><td>No</td></tr><tr><td style=\"white-space:nowrap\">ynk-unknown<a name=\"lt-prostate-questionnaire-options-ynk-unknown\"> </a></td><td>Unknown</td></tr><tr><td style=\"white-space:nowrap\">pirads-cat-1-2<a name=\"lt-prostate-questionnaire-options-pirads-cat-1-2\"> </a></td><td>PI-RADS 1–2</td></tr><tr><td style=\"white-space:nowrap\">pirads-cat-3<a name=\"lt-prostate-questionnaire-options-pirads-cat-3\"> </a></td><td>PI-RADS 3</td></tr><tr><td style=\"white-space:nowrap\">pirads-cat-4<a name=\"lt-prostate-questionnaire-options-pirads-cat-4\"> </a></td><td>PI-RADS 4</td></tr><tr><td style=\"white-space:nowrap\">pirads-cat-5<a name=\"lt-prostate-questionnaire-options-pirads-cat-5\"> </a></td><td>PI-RADS 5</td></tr><tr><td style=\"white-space:nowrap\">pattern4-pct-na<a name=\"lt-prostate-questionnaire-options-pattern4-pct-na\"> </a></td><td>Pattern 4 %: not applicable</td></tr><tr><td style=\"white-space:nowrap\">pattern4-pct-lte5<a name=\"lt-prostate-questionnaire-options-pattern4-pct-lte5\"> </a></td><td>Pattern 4 %: ≤5%</td></tr><tr><td style=\"white-space:nowrap\">pattern4-pct-6-10<a name=\"lt-prostate-questionnaire-options-pattern4-pct-6-10\"> </a></td><td>Pattern 4 %: 6–10%</td></tr><tr><td style=\"white-space:nowrap\">pattern4-pct-gt40<a name=\"lt-prostate-questionnaire-options-pattern4-pct-gt40\"> </a></td><td>Pattern 4 %: >40%</td></tr><tr><td style=\"white-space:nowrap\">tumor-pct-lt1<a name=\"lt-prostate-questionnaire-options-tumor-pct-lt1\"> </a></td><td>Tumour % in biopsy: <1%</td></tr><tr><td style=\"white-space:nowrap\">tumor-pct-1-5<a name=\"lt-prostate-questionnaire-options-tumor-pct-1-5\"> </a></td><td>Tumour % in biopsy: 1–5%</td></tr><tr><td style=\"white-space:nowrap\">tumor-pct-gt90<a name=\"lt-prostate-questionnaire-options-tumor-pct-gt90\"> </a></td><td>Tumour % in biopsy: >90%</td></tr><tr><td style=\"white-space:nowrap\">tumor-pct-uneval<a name=\"lt-prostate-questionnaire-options-tumor-pct-uneval\"> </a></td><td>Tumour %: cannot be evaluated</td></tr><tr><td style=\"white-space:nowrap\">periprostatic-unknown<a name=\"lt-prostate-questionnaire-options-periprostatic-unknown\"> </a></td><td>Periprostatic fat invasion: unidentifiable</td></tr><tr><td style=\"white-space:nowrap\">periprostatic-absent<a name=\"lt-prostate-questionnaire-options-periprostatic-absent\"> </a></td><td>Periprostatic fat invasion: not identified</td></tr><tr><td style=\"white-space:nowrap\">periprostatic-present<a name=\"lt-prostate-questionnaire-options-periprostatic-present\"> </a></td><td>Periprostatic fat invasion: present</td></tr><tr><td style=\"white-space:nowrap\">biopsy-initial<a name=\"lt-prostate-questionnaire-options-biopsy-initial\"> </a></td><td>Initial biopsy</td></tr><tr><td style=\"white-space:nowrap\">biopsy-repeat<a name=\"lt-prostate-questionnaire-options-biopsy-repeat\"> </a></td><td>Repeat biopsy</td></tr><tr><td style=\"white-space:nowrap\">fixative-buffered-formalin<a name=\"lt-prostate-questionnaire-options-fixative-buffered-formalin\"> </a></td><td>10% buffered formalin</td></tr><tr><td style=\"white-space:nowrap\">fixative-unfixed<a name=\"lt-prostate-questionnaire-options-fixative-unfixed\"> </a></td><td>Unfixed (no fixative)</td></tr><tr><td style=\"white-space:nowrap\">dx-n40-gph<a name=\"lt-prostate-questionnaire-options-dx-n40-gph\"> </a></td><td>N40 Glandular prostatic hyperplasia</td></tr><tr><td style=\"white-space:nowrap\">dx-c61<a name=\"lt-prostate-questionnaire-options-dx-c61\"> </a></td><td>C61 Malignant neoplasm of prostate</td></tr><tr><td style=\"white-space:nowrap\">ct-1c<a name=\"lt-prostate-questionnaire-options-ct-1c\"> </a></td><td>cT1c</td></tr><tr><td style=\"white-space:nowrap\">ct-2<a name=\"lt-prostate-questionnaire-options-ct-2\"> </a></td><td>cT2</td></tr><tr><td style=\"white-space:nowrap\">ct-3a<a name=\"lt-prostate-questionnaire-options-ct-3a\"> </a></td><td>cT3a</td></tr><tr><td style=\"white-space:nowrap\">ct-3b<a name=\"lt-prostate-questionnaire-options-ct-3b\"> </a></td><td>cT3b</td></tr><tr><td style=\"white-space:nowrap\">op-transperineal<a name=\"lt-prostate-questionnaire-options-op-transperineal\"> </a></td><td>Transperineal biopsy</td></tr><tr><td style=\"white-space:nowrap\">op-transrectal<a name=\"lt-prostate-questionnaire-options-op-transrectal\"> </a></td><td>Transrectal biopsy</td></tr><tr><td style=\"white-space:nowrap\">proc-systematic<a name=\"lt-prostate-questionnaire-options-proc-systematic\"> </a></td><td>Systematic biopsy</td></tr><tr><td style=\"white-space:nowrap\">proc-adaptive<a name=\"lt-prostate-questionnaire-options-proc-adaptive\"> </a></td><td>Adaptive biopsy</td></tr><tr><td style=\"white-space:nowrap\">proc-systematic-targeted<a name=\"lt-prostate-questionnaire-options-proc-systematic-targeted\"> </a></td><td>Systematic + targeted biopsy</td></tr><tr><td style=\"white-space:nowrap\">proc-applicative-perifocal<a name=\"lt-prostate-questionnaire-options-proc-applicative-perifocal\"> </a></td><td>Applicative + perifocal biopsy</td></tr><tr><td style=\"white-space:nowrap\">perineural-present<a name=\"lt-prostate-questionnaire-options-perineural-present\"> </a></td><td>Perineural invasion present</td></tr><tr><td style=\"white-space:nowrap\">perineural-absent<a name=\"lt-prostate-questionnaire-options-perineural-absent\"> </a></td><td>Perineural invasion not identified</td></tr><tr><td style=\"white-space:nowrap\">perineural-ambiguous<a name=\"lt-prostate-questionnaire-options-perineural-ambiguous\"> </a></td><td>Perineural invasion ambiguous</td></tr><tr><td style=\"white-space:nowrap\">perineural-uneval<a name=\"lt-prostate-questionnaire-options-perineural-uneval\"> </a></td><td>Perineural invasion cannot be evaluated</td></tr><tr><td style=\"white-space:nowrap\">lymphovascular-present<a name=\"lt-prostate-questionnaire-options-lymphovascular-present\"> </a></td><td>Lymphovascular invasion identifiable</td></tr><tr><td style=\"white-space:nowrap\">lymphovascular-absent<a name=\"lt-prostate-questionnaire-options-lymphovascular-absent\"> </a></td><td>Lymphovascular invasion unidentifiable / not available</td></tr><tr><td style=\"white-space:nowrap\">lymphovascular-ambiguous<a name=\"lt-prostate-questionnaire-options-lymphovascular-ambiguous\"> </a></td><td>Lymphovascular invasion ambiguous</td></tr><tr><td style=\"white-space:nowrap\">lymphovascular-uneval<a name=\"lt-prostate-questionnaire-options-lymphovascular-uneval\"> </a></td><td>Lymphovascular invasion cannot be evaluated</td></tr></table></div>"
},
"url" : "https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options",
"version" : "0.0.1",
"name" : "ProstateQuestionnaireOptions",
"title" : "Prostate questionnaire answer options (illustrative)",
"status" : "draft",
"experimental" : true,
"date" : "2026-03-31T08:54:25+00:00",
"publisher" : "Lithuanian Medical Library",
"contact" : [
{
"name" : "Lithuanian Medical Library",
"telecom" : [
{
"system" : "url",
"value" : "https://medicinosnk.lt"
},
{
"system" : "email",
"value" : "info@medicinosnk.lt"
}
]
}
],
"description" : "Illustrative codes for **Questionnaire** answer options for prostate ESPBI-style forms in this IG. Register or replace with national coded values in production.",
"jurisdiction" : [
{
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "LT"
}
]
}
],
"caseSensitive" : true,
"content" : "complete",
"count" : 82,
"concept" : [
{
"code" : "specimen-satisfactory",
"display" : "Specimen satisfactory for evaluation"
},
{
"code" : "specimen-limited",
"display" : "Specimen satisfactory but limited"
},
{
"code" : "specimen-insufficient",
"display" : "Insufficient tissue for diagnosis"
},
{
"code" : "treatment-unknown",
"display" : "Treatment effect unknown"
},
{
"code" : "treatment-unidentifiable",
"display" : "Treatment effect unidentifiable"
},
{
"code" : "treatment-radiotherapy",
"display" : "Observed radiotherapy effect"
},
{
"code" : "treatment-hormone",
"display" : "Observed hormone therapy effect"
},
{
"code" : "treatment-other",
"display" : "Observed other therapy effect"
},
{
"code" : "hist-acinar",
"display" : "Acinar adenocarcinoma (conventional)"
},
{
"code" : "hist-acinar-signet-ring",
"display" : "Acinar adenocarcinoma, signet-ring cell-like"
},
{
"code" : "hist-acinar-pleomorphic",
"display" : "Acinar adenocarcinoma, pleomorphic giant cell"
},
{
"code" : "hist-acinar-sarcomatoid",
"display" : "Acinar adenocarcinoma, sarcomatoid"
},
{
"code" : "hist-acinar-pin-like",
"display" : "Acinar adenocarcinoma, PIN-like"
},
{
"code" : "hist-idc-isolated",
"display" : "Isolated intraductal carcinoma"
},
{
"code" : "hist-ductal",
"display" : "Ductal adenocarcinoma"
},
{
"code" : "hist-adenosquamous",
"display" : "Adenosquamous carcinoma"
},
{
"code" : "hist-squamous",
"display" : "Squamous cell carcinoma"
},
{
"code" : "hist-basal-cell",
"display" : "Basal cell (adenoid cystic) carcinoma"
},
{
"code" : "hist-neuro-adeno",
"display" : "Adenocarcinoma with neuroendocrine differentiation"
},
{
"code" : "hist-neuro-well-diff",
"display" : "Well-differentiated neuroendocrine tumor"
},
{
"code" : "hist-neuro-small-cell",
"display" : "Small cell neuroendocrine carcinoma"
},
{
"code" : "hist-neuro-large-cell",
"display" : "Large cell neuroendocrine carcinoma"
},
{
"code" : "hist-unassessable",
"display" : "Carcinoma, type unassessable"
},
{
"code" : "hist-other",
"display" : "Other histological type (see comment)"
},
{
"code" : "isup-gg1",
"display" : "ISUP Grade Group 1 (Gleason 3+3)"
},
{
"code" : "isup-gg2",
"display" : "ISUP Grade Group 2 (Gleason 3+4)"
},
{
"code" : "isup-gg3",
"display" : "ISUP Grade Group 3 (Gleason 4+3)"
},
{
"code" : "isup-gg4",
"display" : "ISUP Grade Group 4 (Gleason 4+4 or equivalent)"
},
{
"code" : "isup-gg5",
"display" : "ISUP Grade Group 5 (Gleason 4+5 / 5+4 / 5+5)"
},
{
"code" : "idc-absent",
"display" : "Intraductal carcinoma not identified"
},
{
"code" : "idc-present",
"display" : "Intraductal carcinoma identifiable"
},
{
"code" : "cribriform-na",
"display" : "Cribriform not applicable"
},
{
"code" : "cribriform-unknown",
"display" : "Cribriform undefined"
},
{
"code" : "cribriform-present",
"display" : "Cribriform identifiable"
},
{
"code" : "dre-not-done",
"display" : "DRE not performed"
},
{
"code" : "dre-normal",
"display" : "DRE normal"
},
{
"code" : "dre-suspicious",
"display" : "DRE suspicious"
},
{
"code" : "referral-screening",
"display" : "Referral for screening"
},
{
"code" : "referral-elevated-psa",
"display" : "Referral for elevated PSA"
},
{
"code" : "referral-other",
"display" : "Other referral reason"
},
{
"code" : "ynk-yes",
"display" : "Yes"
},
{
"code" : "ynk-no",
"display" : "No"
},
{
"code" : "ynk-unknown",
"display" : "Unknown"
},
{
"code" : "pirads-cat-1-2",
"display" : "PI-RADS 1–2"
},
{
"code" : "pirads-cat-3",
"display" : "PI-RADS 3"
},
{
"code" : "pirads-cat-4",
"display" : "PI-RADS 4"
},
{
"code" : "pirads-cat-5",
"display" : "PI-RADS 5"
},
{
"code" : "pattern4-pct-na",
"display" : "Pattern 4 %: not applicable"
},
{
"code" : "pattern4-pct-lte5",
"display" : "Pattern 4 %: ≤5%"
},
{
"code" : "pattern4-pct-6-10",
"display" : "Pattern 4 %: 6–10%"
},
{
"code" : "pattern4-pct-gt40",
"display" : "Pattern 4 %: >40%"
},
{
"code" : "tumor-pct-lt1",
"display" : "Tumour % in biopsy: <1%"
},
{
"code" : "tumor-pct-1-5",
"display" : "Tumour % in biopsy: 1–5%"
},
{
"code" : "tumor-pct-gt90",
"display" : "Tumour % in biopsy: >90%"
},
{
"code" : "tumor-pct-uneval",
"display" : "Tumour %: cannot be evaluated"
},
{
"code" : "periprostatic-unknown",
"display" : "Periprostatic fat invasion: unidentifiable"
},
{
"code" : "periprostatic-absent",
"display" : "Periprostatic fat invasion: not identified"
},
{
"code" : "periprostatic-present",
"display" : "Periprostatic fat invasion: present"
},
{
"code" : "biopsy-initial",
"display" : "Initial biopsy"
},
{
"code" : "biopsy-repeat",
"display" : "Repeat biopsy"
},
{
"code" : "fixative-buffered-formalin",
"display" : "10% buffered formalin"
},
{
"code" : "fixative-unfixed",
"display" : "Unfixed (no fixative)"
},
{
"code" : "dx-n40-gph",
"display" : "N40 Glandular prostatic hyperplasia"
},
{
"code" : "dx-c61",
"display" : "C61 Malignant neoplasm of prostate"
},
{
"code" : "ct-1c",
"display" : "cT1c"
},
{
"code" : "ct-2",
"display" : "cT2"
},
{
"code" : "ct-3a",
"display" : "cT3a"
},
{
"code" : "ct-3b",
"display" : "cT3b"
},
{
"code" : "op-transperineal",
"display" : "Transperineal biopsy"
},
{
"code" : "op-transrectal",
"display" : "Transrectal biopsy"
},
{
"code" : "proc-systematic",
"display" : "Systematic biopsy"
},
{
"code" : "proc-adaptive",
"display" : "Adaptive biopsy"
},
{
"code" : "proc-systematic-targeted",
"display" : "Systematic + targeted biopsy"
},
{
"code" : "proc-applicative-perifocal",
"display" : "Applicative + perifocal biopsy"
},
{
"code" : "perineural-present",
"display" : "Perineural invasion present"
},
{
"code" : "perineural-absent",
"display" : "Perineural invasion not identified"
},
{
"code" : "perineural-ambiguous",
"display" : "Perineural invasion ambiguous"
},
{
"code" : "perineural-uneval",
"display" : "Perineural invasion cannot be evaluated"
},
{
"code" : "lymphovascular-present",
"display" : "Lymphovascular invasion identifiable"
},
{
"code" : "lymphovascular-absent",
"display" : "Lymphovascular invasion unidentifiable / not available"
},
{
"code" : "lymphovascular-ambiguous",
"display" : "Lymphovascular invasion ambiguous"
},
{
"code" : "lymphovascular-uneval",
"display" : "Lymphovascular invasion cannot be evaluated"
}
]
}